American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause–2017 Update

Cobin, Rhoda H.; Goodman, Neil F.

doi:10.4158/ep171828.ps

Cited by 158 publications

(109 citation statements)

References 52 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no evidence that any osteoporosis therapy increases the risk or severity of COVID‐19 infection or alters the disease course (in either a positive or negative way). However, there are early signals that COVID‐19 may be accompanied by an increased risk for hypercoagulable complications, in which case caution may be warranted for estrogen and raloxifene use, both of which may modestly increase thrombotic risk . It may therefore be prudent to instruct patients to temporarily discontinue these hormonal agents if they develop viral respiratory symptoms.…”

Section: Pharmacologic Osteoporosis Treatmentmentioning

confidence: 99%

Osteoporosis Management in the Era of COVID-19

Tsourdi

Clarke

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available.

show abstract

Section: Pharmacologic Osteoporosis Treatmentmentioning

confidence: 99%

Osteoporosis Management in the Era of COVID-19

Tsourdi

Clarke

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…The findings of these studies suggest that HRT is effective. However, HRT may increase the risk of thrombogenicity, and expert recommendations exclude elderly patients and those with a history of diabetes, coronary artery disease, stroke or long‐term menopause from the indications for HRT . Another concern is that the effectiveness of HRT is not dose‐dependent.…”

Section: Introductionmentioning

confidence: 99%

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives

Imamura

Shinozaki

Okada-Ogawa

et al. 2019

J of Oral Rehabilitation

View full text Add to dashboard Cite

Burning mouth syndrome (BMS) is a chronic oro-facial pain disorder of unknown cause. It is more common in peri-and post-menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line-derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network-related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first-line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well-designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. K E Y W O R D Sburning mouth syndrome, central pain modulation, menopause, neuroprotective steroids | 575 IMAMURA et Al. | INTRODUC TI ONBurning mouth symptoms that occurred as secondary phenomena attributable to local conditions 1-9 were previously referred to as "secondary" burning mouth syndrome (BMS), 10 but BMS now refers only to burning symptoms not attributable to local or systemic causes. 11 After excluding such conditions, some common characteristics of BMS are important. Burning sensations are usually bilateral, and intensity fluctuates. 2 The most common site is the tip of the tongue, but pain is often noted at the lateral border of the tongue, lips and hard palate. 12 Affected persons often complain of dysgeusia, 13 which may be accompanied by subjective xerostomia. 14 Peri-and post-menopausal women are predisposed to the condition.Some patients exhibit depressive symptoms and anxiety 15-18 and may express concern regarding the presence of a malignant condition. 10,16 Psychosocial stressors can trigger or worsen pain, 15,19 while eating and drinking usually alleviate pain. 10,20 These manifestations are characteristic features of BMS and should not be excluded as secondary signs or symptoms of primary disease. Agreement on these clinical features yields important clues in understanding the underlying pathoph...

show abstract

“…Si bien la disfunción del endotelio en la menopausia es causada por la reducción o abolición de factores vasoprotectores, induciendo una medio proinflamatorio, proliferativo y procoagulatorio, la evidencia de que la terapia de reemplazo hormonal sea efectiva es controvertida (3,7,8,12,-14). Aún así, está recomendada en mujeres con síntomas menopáusicos con edad <60 años, con inicio de la menopausia de <10 años, colesterol LDL <130 mg/dL, ausencia de síndrome metabólico y del genotipo de ausencia del factor V Leiden (28).…”

Section: Elección Del Tratamiento Antihipertensivo En La Menopausiaunclassified

Treatment of arterial hypertension in menopause

Delor¹,

Aquino

2018

An. Fac. Cienc. Méd. (Asunción)

View full text Add to dashboard Cite

RESUMENIntroducción: la hipertensión arterial en la menopausia está influencia por el descenso de estrógenos que induce disfunción endotelial y aumento del índice de masa corporal. Objetivos: describir los mecanismos fisiopatológicos de la hipertensión arterial en la menopausia y los antihipertensivos recomendados en la actualidad. Metodología: se realizó una revisión bibliográfica en las bases de datos PubMed y SciELO utilizando las palabras claves: hipertensión arterial y menopausia. Resultados: no existen diferencias en la respuesta a los diferentes antihipertensivos y ambos sexos se benefician en la reducción de la morbimortalidad cardiovascular con la disminución de la presión arterial. La efectividad preventiva de complicaciones cardiovasculares con los antihipertensivos no difiere según el sexo y por lo tanto la elección del medicamento no puede basarse en este criterio en mujeres menopáusicas. Conclusión: la deficiencia de estrógeno induce disfunción endotelial y aumento del índice de masa corporal siendo las principales causas de hipertensión en la menopausia. Todos los antihipertensivos están recomendados en la menopausia.Palabras Clave: Hipertensión Arterial, Menopausia.ABSTRACT Introduction: Arterial hypertension in menopause is influenced by the decrease in estrogen that induces endothelial dysfunction and increase in body mass index. Objectives: to describe the physiopathological mechanisms of arterial hypertension in menopause and the currently recommended antihypertensive drugs. Methodology: We conducted a literature review in PubMed and SciELO databases using the key words: arterial hypertension and menopause. Results: There are no differences in the response to different antihypertensive drugs and both sexes benefit in the reduction of cardiovascular morbidity and mortality with the reduction of blood pressure. The preventive effectiveness of cardiovascular complications with antihypertensive drugs does not differ according to sex and therefore the choice of medication cannot be based on this criterion in menopausal women. Conclusions: Estrogen deficiency induces endothelial dysfunction and increase in body mass index being the main causes of hypertension in menopause. All antihypertensive drugs are recommended at menopause.

show abstract

American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause–2017 Update

Cited by 158 publications

References 52 publications

Osteoporosis Management in the Era of COVID-19

Osteoporosis Management in the Era of COVID-19

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives

Treatment of arterial hypertension in menopause

Contact Info

Product

Resources

About